Ipsen (IPSEY) News Today $27.28 -0.73 (-2.61%) (As of 12/20/2024 05:55 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncologyDecember 3, 2024 | markets.businessinsider.comIpsen And Biomunex Reach Licensing Agreement For MAIT Cell Engager In Immuno-OncologyDecember 3, 2024 | markets.businessinsider.comBylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGSNovember 18, 2024 | uk.finance.yahoo.comIpsen Pharma: Bylvay (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGSNovember 18, 2024 | finanznachrichten.deIpsen Pharma: Iqirvo (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritusNovember 16, 2024 | finanznachrichten.deIqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritusNovember 16, 2024 | finance.yahoo.comIpsen's elafibranor recommended for use in patients with rare liver diseaseOctober 27, 2024 | msn.comIpsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidanceOctober 23, 2024 | uk.finance.yahoo.comIpsen Q3 Sales Increase; Lifts FY24 Outlook - Quick FactsOctober 23, 2024 | markets.businessinsider.comIpsen (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average - Time to Sell?Ipsen (OTCMKTS:IPSEY) Stock Crosses Above Two Hundred Day Moving Average - What's Next?October 22, 2024 | marketbeat.comIpsen Pharma: Ipsen receives its second Shingo Prize for operational excellenceOctober 14, 2024 | finanznachrichten.deIpsen receives its second Shingo Prize for operational excellenceOctober 14, 2024 | finance.yahoo.comIpsen Pharma: Ipsen's Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver diseaseSeptember 23, 2024 | finanznachrichten.deIpsen: European Commission Approves Kayfanda - Quick FactsSeptember 23, 2024 | markets.businessinsider.comIpsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver diseaseSeptember 23, 2024 | finance.yahoo.comIpsen Pharma: Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decadeSeptember 20, 2024 | finanznachrichten.deIpsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decadeSeptember 20, 2024 | markets.businessinsider.comIpsen: European Commission Grants Conditional Marketing Authorization For IqirvoSeptember 20, 2024 | markets.businessinsider.comIpsen (OTCMKTS:IPSEY) Upgraded by Royal Bank of Canada to "Moderate Buy"Royal Bank of Canada upgraded shares of Ipsen from a "hold" rating to a "moderate buy" rating in a report on Monday.September 20, 2024 | marketbeat.comIpsen (0MH6) Receives a Buy from Kepler CapitalSeptember 18, 2024 | markets.businessinsider.comIpsen (OTCMKTS:IPSEY) Shares Cross Above 200-Day Moving Average of $30.20Ipsen (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average of $30.20September 17, 2024 | marketbeat.comIpsen Pharma: Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumorsSeptember 16, 2024 | finanznachrichten.deFinal results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumorsSeptember 16, 2024 | finance.yahoo.comEmployee of French drugmaker Ipsen to plead guilty to US insider tradingSeptember 11, 2024 | reuters.comIpsen (OTCMKTS:IPSEY) Stock Price Passes Above 200-Day Moving Average of $30.04Ipsen (OTCMKTS:IPSEY) Stock Price Crosses Above 200-Day Moving Average of $30.04August 29, 2024 | marketbeat.comShort Interest in Ipsen S.A. (OTCMKTS:IPSEY) Increases By 200.0%Ipsen S.A. (OTCMKTS:IPSEY - Get Free Report) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 300 shares, a growth of 200.0% from the July 15th total of 100 shares. Based on an average daily volume of 1,300 shares, the short-interest ratio is presently 0.2 days.August 13, 2024 | marketbeat.comIpsen SA ADR (IPSEY)July 31, 2024 | investing.comIpsen S.A. (0MH6.IL)July 25, 2024 | ca.finance.yahoo.comIpsen S.A. Non-GAAP EPS of €4.78, revenue of €1.66B; raises FY24 outlookJuly 25, 2024 | msn.comIpsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)July 25, 2024 | globenewswire.comShort Interest in Ipsen S.A. (OTCMKTS:IPSEY) Decreases By 80.0%Ipsen S.A. (OTCMKTS:IPSEY - Get Free Report) saw a large drop in short interest in June. As of June 15th, there was short interest totalling 300 shares, a drop of 80.0% from the May 31st total of 1,500 shares. Based on an average trading volume of 1,400 shares, the short-interest ratio is presently 0.2 days.June 28, 2024 | marketbeat.comAnnual General Meeting of Ipsen S.A. held on 28 May 2024May 28, 2024 | globenewswire.comDescription of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.'s Annual General Meeting on 28 May 2024May 28, 2024 | globenewswire.comIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General MeetingMay 7, 2024 | globenewswire.comIpsen appoints Keira Driansky as EVP, President of North AmericaMay 2, 2024 | finance.yahoo.comIpsen S.A. reports Q1 results; reaffirms full-year guidanceApril 24, 2024 | msn.comIpsen Q1 Total-sales Up 13.3% At CER; Confirms 2024 Financial GuidanceApril 24, 2024 | markets.businessinsider.comIpsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidanceApril 24, 2024 | finance.yahoo.comIpsen Pharma: Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesApril 23, 2024 | finanznachrichten.deIpsen, Skyhawk Therapeutics To Develop RNA-Modulating Molecules For Rare Neurological DisordersApril 22, 2024 | markets.businessinsider.comIpsen publishes its 2023 Universal Registration DocumentApril 17, 2024 | finance.yahoo.comIpsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For InvestorsApril 5, 2024 | seekingalpha.comMarengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with IpsenApril 2, 2024 | finance.yahoo.comIpsen S.A. publishes its 2023 Consolidated Financial StatementsFebruary 15, 2024 | globenewswire.comIpsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDAFebruary 14, 2024 | financialpost.comIpsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDAFebruary 13, 2024 | finance.yahoo.comIpsen gets FDA approval for pancreatic cancer drug regimenFebruary 13, 2024 | msn.comIpsen Shares Fall After Forecast of Lower MarginFebruary 8, 2024 | marketwatch.comBuilding on solid FY 2023 results, Ipsen anticipates four launches in 2024February 8, 2024 | markets.businessinsider.comIpsen FY23 Profit Flat, Sales Rise; Sees Growth In FY24, Backs Mid-term ViewFebruary 8, 2024 | markets.businessinsider.com Get Ipsen News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter. Email Address 70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << IPSEY Media Mentions By Week IPSEY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPSEY News Sentiment▼0.000.61▲Average Medical News Sentiment IPSEY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPSEY Articles This Week▼01▲IPSEY Articles Average Week Get Ipsen News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IDEXX Laboratories News Lantheus News QuidelOrtho News Neogen News Celldex Therapeutics News Intellia Therapeutics News Myriad Genetics News Oruka Therapeutics News Alpha Teknova News Achieve Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IPSEY) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ipsen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPSEY Stock Alerts